In its pursuit of acquisitions of complementary products and companies, Actavis acquired Furiex Pharmaceuticals in 2014 for its Gastroenterology segment.
The top 10 products across Actavis’s therapeutic segments accounted for approximately 70% of net revenues of segmental revenues in fiscal 2014.
Actavis’s North American Brands segment revenue increased significantly by 336% year-over-year to $4,631.4 million in 2014 from $1,062.5 million in 2013.
Anda, Inc. is the fourth-largest generics distributor in the US, accounting for about 13% of total net revenues in fiscal 2014 and 14% in fiscal 2013.
In October 2012, Actavis completed the acquisition of Actavis Group. In 2013, the company’s revenues outside the US increased to 29% from 16% in 2012.
In 2014, Actavis generated revenue of $13,062.3 million, employed 21,600 workers, and had more than 30 manufacturing and distribution facilities worldwide.
In the commercial business, self-insured coverage means the employer is responsible for the probable claim obligations of the employees.
Recently, Pfizer announced its plans to acquire Hospira. It’s a leading provider of injectable drugs and infusion technologies. It’s a global leader in biosimilars.
Pfizer (PFE) is one of the oldest and largest pharmaceutical companies. It focuses on biopharmaceutical and consumer healthcare products.
Pfizer (PFE) faces foreign exchange, global, legal, and integration risks. These risks are in addition to the pharmaceutical industry’s risks.
Leverage ratios determine the company’s ability to repay its debt. Leverage ratios directly affect the credit ratings. Pfizer has good credit ratings.
Research and development, or R&D, is the most crucial part of business for large pharmaceutical companies like Pfizer. Its R&D expenses were $8.4 billion in 2014.
Pfizer’s (PFE) net revenue decreased by nearly 4% to $49.6 billion in 2014. For the total revenue, biopharmaceuticals’ contributions decreased to 92% in 2014.
The Global Established Pharmaceutical segment deals with products that have or are expected to lose market exclusivity through 2015 in most major markets.
The global GVOC segment is focused on developing and commercializing the vaccines, oncology products, and consumer healthcare products.
The GIP (Global Innovative Pharmaceutical) segment is focused on developing, registering, and commercializing value-creating medicines.
In the last three years, Pfizer (PFE) consistently recorded direct product sales of over $1 billion for each of its ten biopharmaceutical products.
Most of Pfizer’s revenue comes from its biopharmaceutical business. In 2014, over 92% of the total revenue was from the Biopharmaceutical segment.
Pfizer (PFE) is one of the oldest and largest pharmaceutical companies in the US. The company deals in two major business segments.
By revenue, Pfizer is one of the largest pharmaceutical companies. It’s headquartered in New York City. It focuses on prescription and OTC drugs.